BioSpace News Archive

Hutchison brings extensive background in innovative GI product sales and will lead development of commercial organization in preparation for 2019 launch

BioAmber Inc. has initiated a liquidation process pursuant to which offers will be solicited from liquidators and/or strategic buyers to proceed with the liquidation of the company’s assets or a recapitalization transaction with the goal of realizing the greatest value on behalf of the company’s creditors.

The offering is expected to close on or about August 13, 2018, subject to customary closing conditions.

Particle Sciences, Inc. announced the appointment of Robert W. Lee, Ph.D. to the position of President.

Vaccinex, Inc.(Vaccinex), a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, today announced the pricing of its initial public offering of 3,333,334 shares of common stock at a public offering price of $12.00 per share.

Partners with Leading Australian Healthcare Products and Biological Supplier